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Tandem autologous-allogeneic stem cell 
transplantation as a feasible and effective procedure
in high-risk lymphoma patients
Although high-dose chemotherapy is the gold standard
for the treatment of many relapsed or refractory lym-
phomas, the outcome remains unsatisfactory, particularly
in some subsets of patients with adverse prognostic fea-
tures. Here we report the outcome of 111 high-risk lym-
phoma patients treated with a tandem strategy involving
debulking with HDC followed by autologous stem cell
transplantation (ASCT) and subsequent adoptive
immunotherapy consisting of allogeneic stem cell trans-
plantation (SCT; tandem auto-allo). The response rate
after ASCT was 86% and 34 patients (52% of responding
patients) obtained complete remission before allogeneic
SCT. After a median follow up of 38 months after allo-
geneic stem cell transplantation, the 3-year overall sur-
vival,, progression-free survival, non-relapse mortality
and relapse/progression were 68% (95%CI: 59-77), 61%
(95%CI: 52-70), 17% (95%CI: 10-25) and 22% (95%CI:
14-30), respectively. In multivariate analysis, the
response to autologous stem cell transplantation was the
only independent predictive factor of mortality (P=0.05),
whereas autologous stem cell transplantation condition-
ing and the type of allogeneic donor did not significantly
affect survival (P=0.40 and P=0.68, respectively). No sur-
vival difference was observed between Hodgkin and
non-Hodgkin lymphoma patients (P=0.53). 
Salvage chemotherapy followed by high-dose therapy
and autologous sem cell transplantation (ASCT) is recog-
nized as the most effective strategy for relapsed or refrac-
tory Hodgkin lymphoma (HL)  or aggressive non-
Hodgkin lymphoma (NHL).1,2 However, patients with
some adverse prognostic features still have unsatisfactory
outcomes after ASCT alone and may benefit from addi-
tional therapies. Short response duration after first-line
therapy, B symptoms, advanced stage and/or extranodal
disease at relapse and relapse in a previously irradiated
field are among the most recognized adverse prognostic
factors in relapsed/refractory HL patients,3,4 whereas
relapse within one year of diagnosis, prior rituximab ther-
apy and secondary IPI score have been reported in diffuse
large B-cell lymphoma.5 Other prognostic factors have
been identified for relapsed follicular and mantle cell lym-
phoma. Despite the identification of several adverse
prognostic factors, the question about the best therapy
for patients with refractory lymphoma is still open, and
efforts are ongoing in an attempt to investigate the role
and the timing of high-dose chemotherapy, allogeneic
SCT, and investigational drugs. The aim of the present
retrospective analysis is to report data on the feasibility,
toxicity and outcome of tandem auto-allo in 111 adults
with high-risk HL or NHL. Since it is known that the
graft-versus-lymphoma (GvL) effect after allogeneic SCT
is more effective when the tumor burden is minimal or
not detected before transplantation, we explored a tan-
dem strategy combining cytoreduction (through the
administration of HDC followed by ASCT) and the GvL
effect in those high-risk patients for whom ASCT is
expected to produce unsatisfactory results. 
From June 2002 to September 2013, we identified 111
patients with a diagnosis of lymphoproliferative disease
who received tandem auto-allo at any point during their
therapeutic history at two institutions (Istituto Clinico
Humanitas, Milan, Italy; Institut Paoli-Calmettes,
Marseille, France), selected from the internal transplanta-
tion database. The data regarding patients’ age, sex, diag-
nosis, indication for tandem auto-allo, type and number
of previous therapy or therapies, ASCT conditioning,
interval between ASCT and allogeneic SCT, donor type
and HCT-CI score were collected and analyzed as co-
variates in regression analyses; the hematopoietic cell
transplantation-specific comorbidity index was reported
or retrospectively calculated whenever possible.  First-
line therapy was ABVD (HL patients), CHOP or CHOP-
like regimens (patients with aggressive NHL, with the
addition of rituximab in cases of malignant-cell positivity
for CD20) or chemotherapy associations not including
anthracyclines (i.e. R-CVP for indolent NHL). The salvage
regimens were DHAP, IGEV or ICE with the addition of
rituximab for CD20+ lymphomas. As per institutional
guidelines, BEAM or BEAM-like regimens were adminis-
tered in Marseille whereas high-dose melphalan (HD-
Mel) was administered  in Milan. The allogeneic SCT
conditioning regimens were classified as myeloablative
(MAC), reduced intensity (RIC) or non-myeloablative
(NMA) according to working definitions.6 The choice of
the conditioning depended on donor type, patient’s clin-
ical status, and any institutional protocols at the moment
of patient enrollment. Regarding donor selection, when a
patient lacked a suitable HLA-identical sibling, a search
for a 10/10-matched or a 9/10-mismatched unrelated
donor was initiated (only for patients aged ≤ 65 years at
Istituto Clinico Humanitas). Beginning in 2010, in the
absence of either an available HLA-identical sibling or an
unrelated donor at the appropriate time interval, a hap-
loidentical or cord blood donor was identified. Peripheral
blood stem cells was the preferred source from HLA-
identical and mismatched unrelated donors whereas hap-
loidentical donors were scheduled to undergo bone mar-
row harvest under general anesthesia unless contraindi-
cated. Response was assessed using the standard and
revised Cheson criteria, these latter after the introduction
of PET as a tool for response evaluation, occurring in
2003 and progressively used for disease evaluation of HL
and aggressive NHL. The results pertaining to some
patients in this cohort have been published elsewhere.7,8
Patients were followed-up until June 2014. The study
was approved by the IRB of both institutions. 
The main patients’ and transplants’ characteristics are
shown in Table 1. Ten patients were allocated to tandem
auto-allo at diagnosis (n=3 mantle cell, n=3 transformed
follicular, n=3 peripheral T-cell, n=1 NK lymphoma),
based on disease aggressiveness, patient’s physical status
and willingness, clinical judgment. The indication of tan-
dem auto-allo was given before ASCT for all patients and
did not depend on response after ASCT (Table 1). The
median interval between ASCT and allogeneic SCT was
85 days (range: 36-235). After ASCT, median neutrophil
engraftment occurred at day 13 (range: 8-41). NCI-CTC
grade 3-4 mucositis occurred in 49 patients (44%) and at
least one moderate to severe infectious disease was doc-
umented in 34 patients (31%), without significant differ-
ences between (B)EAM and HD-Mel (P=0.69 and P=0.21,
respectively). After allogeneic SCT, median neutrophil
engraftment occurred at day 18 (range 11-42), day 23
(range: 15-32) and day 14 (range: 7-26) after peripheral
blood stem cells, bone marrow and cord blood, respec-
tively. Two graft failures occurred in 2 patients after hap-
loidentical transplantation. Three patients died before
engraftment (2 haploidentical, 1 HLA-identical). Grade 3-
4 mucositis occurred in 7 patients (2 after MAC, 5 after
RIC). The rate of moderate to severe infections during
hospitalization was 0%, 15% and 26% after MAC, RIC
and NMA conditioning, respectively. At the time of
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ASCT, 46 patients (41%) were in complete remission
(CR), 39 (35%) were in partial remission (PR), and 10
(9%) and 16 (15%) had stable (SD) or progressive disease
(PD), respectively. Among the 65 patients with measura-
ble disease before ASCT, response (i.e. CR or PR) was
observed in 56 patients (86% overall response)  without
significant difference between (B)EAM and HD-Mel
(P=0.28). All but one patient in CR before ASCT main-
tained CR before allogeneic SCT. Disease response to
ASCT according to the diagnosis of HL, aggressive NHL
and indolent NHL is shown in Figure 1. After a median
follow up of 38 months after allogeneic SCT, the 3-year
OS and PFS of the entire cohort were 68% (95%CI: 59-
77) and 61% (95%CI: 52-70), respectively. The overall
incidence of grade 2-4 and grade 3-4 acute graft-versus-
host disease (GvHD) and chronic GvHD were 28%
(95%CI: 20-37), 11% (95%CI: 5-17) and 40% (95%CI:
31-50), respectively. At three years, cumulative incidence
of NRM and relapse/progression after allogeneic SCT
were 17% (95%CI: 10-25) and 22% (95%CI: 14-30),
respectively. Survival of patients in CR before allogeneic
SCT was superior to those with active disease and
patients obtaining CR after ASCT had the same survival
probability of those who were already in CR before
ASCT (Figure 2A). The overall mortality hazard ratio
(HR) was 0.40 (95%CI: 0.16-1.00) for responders who
obtained CR vs. non-responders (i.e. patients in SD or
PD; P=0.05), whereas the HR of patients who converted
to PR versus non-responders was 0.67 (95%CI: 0.24-1.90;
P=0.46). In multivariate analysis, response to ASCT was
the only independent predictive factor of OS. The sur-
vival advantage of patients in CR versus those not in CR
was maintained across the three histology groups cited
above (P-value of interaction term: 0.97) (Figures 2B-D).
No statistically significant variable was found in the mul-
tivariate models of OS or RM with the exception of a
higher NRM risk after transplant with a haplo- versus
HLA-identical sibling: HR = 3.55 (95%CI: 1.06-11.89;
P=0.04). However, 4 of the 5 toxic deaths after haplo-
transplants occurred in patients who presented with pro-
gressive disease before ASCT, indeed donor type was no
longer statistically significant in the NRM model after the
variable “disease status before ASCT” was added (data not
shown). Overall mortality did not differ according to the
intensity of conditioning regimen of allogeneic SCT:
among 36 total deaths (36 of 111, 32%), one event
occurred after the 3 MAC (33%), 22 after the 65 RIC
(34%), 13 after the 43 NMA (30%). 
To our knowledge, so far  few reports have been pub-
lished on tandem autologous-allogeneic transplantation
in lymphoma.7,9-11 In addition to a recently reported expe-
rience in HLA-identical setting,7 Cohen et al. reported
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Table 1. Main patients’ and transplant characteristics.
Variable                                              Value                            %
N.                                                                     111                                 100%
Pt. age (median)                                          44                           range: 16-69
Gender                                                                                                      
M                                                                   66                                   59%
F                                                                    45                                   41%
Disease                                                                                                      
HL                                                                 44                                   40%
DLBCL                                                         12                                   11%
FL                                                                 21                                   19%
Transf FL                                                      9                                     8%
MCL                                                              9                                     8%
MZL                                                               1                                     1%
T lymph                                                       13                                   12%
Gray zone                                                    1                                     1%
NK lymphoma                                             1                                     1%
HCT-CI                                                                                                       
0                                                                    31                                   28%
1-2                                                                 27                                   24%
>2                                                                 36                                   33%
missing                                                        17                                   15%
Indication for tandem auto-allo                                                          
primary refractory                                    28                                   25%
no CR after salvage                                  43                                   39%
histology                                                     10                                    9%
relapse after prior ASCT                          6                                     5%
multiple relapses                                     24                                   22%
Prior therapy lines (median) 2          range: 0-7
Prior radiotherapy                                        26                                   23%
ASCT conditioning                                                                                  
BEAM                                                           54                                   49%
EAM¶                                                             8                                     7%
HD-Mel 100@                                               1                                     1%
HD-Mel 140                                                12                                   11%
HD-Mel 200                                                33                                   30%
other°                                                            3                                     3%
Allogeneic SCT conditioning                                                                
MAC*                                                            3                                     3%
RIC§                                                              65                                   58%
NMA#                                                            43                                   39%
Allogeneic stem cell donor                                                                   
HLA-id sibling                                            62                                   56%
MUD 10/10                                                  24                                   22%
MUD 9/10                                                     2                                     2%
haplo                                                            20                                   18%
cord blood$                                                  3                                     3%
GvHD prophylaxis                                                                                   
CsA                                                               59                                   53%
CsA + MMF                                                19                                   17%
CsA + MTX                                                 12                                   11%
FK + MMF + PT-Cy                                  14                                   12%
CsA + MMF + PT-Cy                                 6                                     5%
none                                                              1                                     1%
Graft source                                                                                             
PBSC                                                            91                                   82%
BM                                                                16                                   14%
cord blood                                                   3                                     3%
BM + PBSC                                                 1                                     1%
Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma;
Transf FL: transformed follicular lymphoma; MCL: mantle-cell lymphoma;  MZL: mar-
ginal zone lymphoma; T lymph: T-cell lymphoma (including both ALK+ and ALK-
anaplastic large T-cell lymphoma, peripheral T-cell lymphoma), HCT-CI: hematopoietic
cell transplantation-specific comorbidity index; CR: complete response; BEAM: asso-
ciation of BCNU-etoposide-cytarabine-melphalan; EAM: association of etoposide-
cytarabine-melphalan; HD-Mel: melphalan at doses from 100 to 200 mg/m2; CsA:
cyclosporin A;  MMF: mycophenolate mofetil; MTX: methotrexate; FK: tacrolimus; PT-
Cy: post-transplant high-dose cyclophosphamide; PBSC: peripheral blood stem cells;
BM: bone marrow.  ¶BCNU was not administered if patient’s DLCO < 50. @Dose reduc-
tions may have been realized depending on patient’s age, comorbidities, renal func-
tion; °Associations of: BCNU-thiotepa (n=1), etoposide-melphalan (n=1), BCNU-etopo-
side-cytarabine-cyclophosphamide (n=1); *MAC consists of an association of fludara-
bine-busulfan-ATG (n=3); §RIC include associations of: fludarabine-busulfan-ATG
(n=54), thiotepa-fludarabine-cyclophosphamide +/- ATG (n=6), BEAM (n=2), fludara-
bine-treosulfan-ATG (n=1), thiotepa-fludarabine-ATG-rituximab-TBI 200 cGy (n=1),
thiotepa-melphalan-cyclophosphamide-ATG (n=1); #NMA include associations of: flu-
darabine-cyclophosphamide-TBI 200 cGy (n=22), fludarabine-TBI 200 cGy (n=11),
fludarabine-cyclophosphamide (n=9), fludarabine-melphalan-alemtuzumab-TBI 200
cGy (n=1); $two single and one double unit. NOTE: some proportions may exceed
100% due to rounding.
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Figure 1. Response rate after autologous stem cell transplantation
(ASCT) according to type of conditioning: EAM vs. HD-Mel. Total
patients: n=108. (A) HL n=42 (CR, PR, SD/PD: 14,11,17). (B)
Aggressive NHL n=44 (CR, PR, SD/PD: 24,14,6). (C) Indolent NHL
n=22 (CR/PR, SD/PD: 7,13,2).
A
A
C
B
C D
Figure 2 A-D. Overall survival (OS) and progression-free survival (PFS) according to disease status before allogeneic SCT. Estimates at
three years for all patients. (A) OS: CR before and after autologous SCT (ASCT) (n=45), CR after ASCT (n=34), PR after ASCT (n=22), SD/PD
after ASCT (n=10): 72% (95%CI: 59-85), 76% (95%CI: 61-91), 62% (95%CI: 42-82) and 40% (95%CI: 10-70), respectively; (B) OS according
to CR vs. active disease before allogeneic SCT in HL patients (n=44): 67% (95%CI: 50-84) vs. 44% (95%CI: 16-72); (C) OS according to CR
vs. active disease before allogeneic SCT in aggressive Hodgkin lymphoma (HL)  patients (n=45): 72% (95%CI: 57-87) vs. 56% (95%CI: 23-
89); (D) OS according to CR vs. active disease before allogeneic SCT in indolent HL patients (n=22): 90% (95%CI: 71-100) vs. 70% (95%CI:
42-98). 
B
excellent results in 27 patients with follicular lymphoma
after allogeneic SCT from HLA-identical siblings with
96% OS and PFS at three years. Included in the present
series were only 5 patients affected by follicular lym-
phoma who were transplanted by an HLA-identical
donor after a fludarabine-cyclophosphamide-based con-
ditioning; all are alive and disease-free at last follow up.
A recent prospective study conducted on 30 pediatric
patients affected by high-risk HL and NHL11 found sim-
ilar outcomes compared with ours. Interestingly, the 3-
year PFS of the 39 patients with aggressive NHL and
chemosensitive disease (i.e. CR or PR before ASCT) was
65% (95%CI: 50-80) in our series; this finding appears to
compare favorably with both the CORAL5 and CIBMTR
studies,12 which reported a 3-year PFS of 53% and a 3-
year OS of 50% in the same population, respectively. In
particular, Gisselbrecht et al.5 found a 39% PFS at three
years in patients with unfavorable prognostic factors and
who underwent ASCT. We believe that the GvL effect
may have contributed to the fact that 2 of 3 of patients
are alive and disease-free at three years from transplant in
our cohort. Recently, Glass et al.13 reported a promising
52% OS in a phase II trial with myeloablative allogeneic
SCT in aggressive NHL patients, of whom 55% were
classified as chemorefractory; the same study reported a
32% NRM, partially counterbalancing the beneficial GvL
effect. A randomized trial would be of great interest in
this subset of very high-risk patients. Another trial evalu-
ating a myeloablative conditioning followed by allogene-
ic SCT (without prior ASCT) found an impressive 68%
PFS among refractory HL patients.14 The inferior out-
come observed in our cohort may be explained at least
in part by the slightly different population under investi-
gation as 41% (18 of 44) of HL patients in our series
were in SD or PD after salvage therapy versus 20% (5 of
25) in the UK trial.14 An indirect role played by alem-
tuzumab against Reed-Stenberg cells could also be advo-
cated.15 Unexpectedly, we found no moderate or severe
infections after MAC and more events after NMA than
RIC; however, we believe that these data have to be
interpreted with caution due to the fact that only 3
patients received MAC (all with an association of flu-
darabine-busulfan-ATG using 3 days of busulfan, namely
reduced-toxicity conditioning) and that the difference
between NMA and RIC is not statistically significant
(P=0.22 by c2).  
In conclusion, our experience with tandem autologous-
allogeneic transplantation in 111 adult patients affected
by high-risk HL and NHL suggests that this is a feasible
and effective procedure for a selected population. Here,
high-dose chemotherapy administered 2-3 months
before allogeneic SCT provided a 86% response rate
among patients who were not in CR before ASCT and,
notably, those patients converting to CR had the same
survival as those who were already in CR, thus under-
scoring the importance of further tumor shrinkage before
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Figure 2 E-H (cont.). PFS: CR before and after ASCT (n=45), CR after ASCT (n=34), PR after ASCT (n=22), SD/PD after ASCT (n=10): 68%
(95%CI: 54-82), 61% (95%CI: 45-77), 54% (95%CI: 34-74) and 40% (95%CI: 10-70), respectively; (F) PFS according to CR vs. active disease
before allogeneic SCT in HL patients (n=44): 51% (95%CI: 33-69) vs. 37% (95%CI: 10-64); (G) PFS according to CR vs. active disease before
allogeneic SCT in aggressive NHL patients (n=45): 68% (95%CI: 52-84) vs. 56% (95%CI: 23-89); (H) PFS according to CR vs. active disease
before allogeneic SCT in indolent HL patients (n=22): 90% (95%CI: 71-100) vs. 60% (95%CI: 29-91).
allogeneic immunotherapy in this subset of high-risk
patients, irrespective of the conditioning intensity before
allogeneic SCT. In our hands, BEAM and HD-Mel provid-
ed comparable results, both in terms of toxicity and effi-
cacy against lymphoma.
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